MX2022013661A - Vacuna y uso de la misma en la profilaxis y terapia de betacoronavirus. - Google Patents

Vacuna y uso de la misma en la profilaxis y terapia de betacoronavirus.

Info

Publication number
MX2022013661A
MX2022013661A MX2022013661A MX2022013661A MX2022013661A MX 2022013661 A MX2022013661 A MX 2022013661A MX 2022013661 A MX2022013661 A MX 2022013661A MX 2022013661 A MX2022013661 A MX 2022013661A MX 2022013661 A MX2022013661 A MX 2022013661A
Authority
MX
Mexico
Prior art keywords
betacoronavirus
antigen
unit
vaccine
prophylaxis
Prior art date
Application number
MX2022013661A
Other languages
English (en)
Spanish (es)
Inventor
Monika Sekelja
Agnete Brunsvik Fredriksen
Karoline Schjetne
Gunnstein Norheim
Elisabeth Stubsrud
Original Assignee
Nykode Therapeutics ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nykode Therapeutics ASA filed Critical Nykode Therapeutics ASA
Publication of MX2022013661A publication Critical patent/MX2022013661A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022013661A 2020-05-01 2021-05-03 Vacuna y uso de la misma en la profilaxis y terapia de betacoronavirus. MX2022013661A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA202070282 2020-05-01
DKPA202070293 2020-05-06
DKPA202070735 2020-11-05
DKPA202070820 2020-12-08
DKPA202170069 2021-02-15
PCT/EP2021/061602 WO2021219897A1 (en) 2020-05-01 2021-05-03 Betacoronavirus prophylaxis and therapy

Publications (1)

Publication Number Publication Date
MX2022013661A true MX2022013661A (es) 2022-11-30

Family

ID=75870604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013661A MX2022013661A (es) 2020-05-01 2021-05-03 Vacuna y uso de la misma en la profilaxis y terapia de betacoronavirus.

Country Status (11)

Country Link
US (1) US20230165952A1 (cg-RX-API-DMAC7.html)
EP (1) EP4143210A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524054A (cg-RX-API-DMAC7.html)
KR (1) KR20230005962A (cg-RX-API-DMAC7.html)
CN (1) CN116096735A (cg-RX-API-DMAC7.html)
AU (1) AU2021262521A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021905A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176527A1 (cg-RX-API-DMAC7.html)
IL (1) IL297621A (cg-RX-API-DMAC7.html)
MX (1) MX2022013661A (cg-RX-API-DMAC7.html)
WO (1) WO2021219897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
CN112028978B (zh) * 2020-09-07 2023-06-16 重庆医科大学 新冠病毒特异性cd8+t细胞表位肽及其应用
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
IL308310A (en) 2021-05-10 2024-01-01 Nykode Therapeutics ASA Co-expression of immune-stimulating structures and compounds
WO2022238432A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunoinhibitory compounds
TW202334429A (zh) * 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CN113801209B (zh) * 2021-11-16 2022-02-11 浙江普康生物技术股份有限公司 一种具有广谱中和活性的新型冠状病毒重组蛋白及其制备方法
GB202201765D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Methods
CN114907452B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽
CN114832099B (zh) * 2022-04-08 2023-11-28 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂
LU102995B1 (en) * 2022-08-17 2024-02-19 PMCR GmbH Immunization against coronavirus
EP4572778A1 (en) * 2022-08-17 2025-06-25 Pmcr Gmbh Immunization against viral infections disease(s)
WO2024038157A1 (en) * 2022-08-17 2024-02-22 PMCR GmbH Immunization against coronavirus
WO2024044747A2 (en) * 2022-08-25 2024-02-29 University Of Florida Research Foundation, Inc. Immunogenic composition and uses thereof
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
US20260193669A1 (en) 2022-11-09 2026-07-09 Nykode Therapeutics ASA Co-Expression of Constructs and Polypeptides
EP4651892A2 (en) * 2023-01-20 2025-11-26 Duke University Epitope-scaffold immunogens for pancoronavirus vaccines
CN121263427A (zh) * 2023-04-07 2026-01-02 国立大学法人大阪大学 滤泡辅助性T细胞诱导性SARS-CoV-2刺突蛋白的部分肽
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途
CN119143850A (zh) * 2024-08-20 2024-12-17 复旦大学 广谱抑制流感病毒的多肽及在预防和/或治疗流感病毒感染中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215489B2 (en) * 2003-02-25 2010-07-15 Nykode Therapeutics ASA Modified antibody
WO2011161244A1 (en) * 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
EP3533462A1 (en) 2011-12-21 2019-09-04 Vaccibody AS Vaccines against hpv
JP2019505512A (ja) * 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
EP3678699A1 (en) * 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
CN113631185A (zh) 2019-02-27 2021-11-09 尼克塔治疗公司 用于治疗癌症的免疫治疗组合
LT3972987T (lt) * 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
WO2021216954A1 (en) * 2020-04-23 2021-10-28 Alpha Beta Holdings, Llc Compositions and methods for treating or preventing virus infection

Also Published As

Publication number Publication date
IL297621A (en) 2022-12-01
KR20230005962A (ko) 2023-01-10
US20230165952A1 (en) 2023-06-01
CN116096735A (zh) 2023-05-09
AU2021262521A1 (en) 2022-12-08
JP2023524054A (ja) 2023-06-08
CA3176527A1 (en) 2021-11-04
BR112022021905A2 (pt) 2022-12-13
WO2021219897A1 (en) 2021-11-04
EP4143210A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
BR112022021905A2 (pt) Vacina, polinucleotídeo, vetor, célula hospedeira, polipeptídeo, proteína dimérica, e, métodos para preparar a vacina e para tratar um sujeito que tem sofrido de uma infecção pelo betacoronavírus ou que está em necessidade de prevenção do mesmo
Eliasson et al. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection
Mooi Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
MX2020007675A (es) Induccion y mejora de respuestas inmunes utilizando sistemas de replicon recombinante.
US12331083B2 (en) Immunogenic compositions to treat and prevent microbial infections
MX2011008791A (es) Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
Pedrazzoli et al. Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM)
PH12015501519A1 (en) Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
Dong et al. Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112016002354A2 (pt) composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
PH12013500133A1 (en) Inactivated varicella zoster virus vaccines, methods of production, and uses thereof
Chen et al. Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen against dengue virus serotype 2 infection
TW201613638A (en) Antibody guided vaccines and methods of use for generation of rapid mature immune responses
MX2016000107A (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
Hung et al. Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus
WO2013173256A3 (en) New and improved influenza vaccines
UY32876A (es) Régimen de inmunización por sensibilización-refuerzo heteróloga
Choi et al. Humoral and cellular immunogenicity induced by avian influenza A (H7N9) DNA vaccine in mice
US20250304627A1 (en) Immunogenic Compositions to Treat and Prevent Microbial Infections
WO2012178078A3 (en) Use of yscf, truncated yscf and yscf homologs as adjuvants
WO2019075300A3 (en) Mayaro virus consensus antigens, dna antibody constructs for use against mayaro virus, and combinations thereof